In conclusion, the in‐depth analysis of the SOFT study suggests that HER2 status and trastuzumab adjuvant treatment influence the benefit of OFS treatment, and it is necessary to conduct research on premenopausal patients with HR+/HER2+ early‐stage breast cancer who received trastuzumab. Here, ERBB2 is linked to breast cancer.